Shots:
GO to receive $20.5M up front, ~$763M in milestones & contingency fees. The companies collaborated to identify novel Abs with high affinity for 2 different glycoprotein targets & use these Abs in a variety of therapeutic approaches
GO will be responsible to discover high-affinity Abs against 2 targets. Astellas will lead the research activities, clinical development & commercialization of the therapies that derived from the Abs
The collaboration will combine GO’s targets & Abs with Astellas’ ACCEL technology for cancer treatments with a greater therapeutic index. Oncologists will be able to improve the efficacy of Abs-based immunotherapies for solid tumors while causing less harm to healthy tissues
Ref: PR Newswire | Image: Astellas
